ACCURATE & RELIABLE THIRD PARTY LP(a) REAGENTS


Lipoprotein (a) or Lp(a) screening is recommended at least once in all adults to identify those at high risk of heart disease or stroke. Screening is also advised in youths with a family history of


stroke, high Lp(a) or premature ASCVD. To allow accurate and reliable screening, assays suffering minimal apo(a) size related bias are recommended.


Traceable to WHO/IFCC reference material (IFCC SRM 2B)


Available for use on most clinical chemistry analysers


Liquid ready-to-use reagents for added convenience


Five-point calibrator with accuracy-based


assigned target values (in nmol/l) is available, accurately reflecting the heterogeneity of the apo(a) isoforms.


The Randox Lp(a) assay demonstrates excellent performance, evidenced by a correlation coefficient of r=0.995 when compared with other commercially available methods and a within-run precision of less than 2.54%.


FDA 510(k) cleared for mg/dL units only, measuring Lp(a) in nmol/L is not FDA approved for the USA market.


+44 (0) 28 9442 2413 | reagents@randox.com


Product availability may vary from country to country. Some products may be for Research use Only. For more information on product application and availability, please contact your local Randox representative.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60